Epigenetic drugs are an emerging class of cancer therapeutics. In this article, Ph.D. candidate Roshan Chikarmane introduces Foghorn Therapeutics, its co-founder, Cigall Kadoch, and the science behind their drug development program.
About Roshan Chikarmane
Posts by Roshan Chikarmane:
Ph.D. candidate Roshan Chikarmane identifies key drivers of rising drug prices and introduces corresponding interventions that are being undertaken by business leaders to shift industry trends toward more affordable health care.
The fruits of modern molecular biology offer us a powerful tool that allows us to engineer the genetic code of virtually any organism. Early therapeutic applications could foreshadow an inflection point for the positioning of genome engineering in modern health care.
The benefits of detecting and treating cancer at early developmental stages have long been observed by clinical oncologists. Colonoscopies as well as other methods for early detection have been estimated to prevent as many as 60% of deaths attributable to colorectal cancer by identifying and removing precancerous growths1. More broadly, patients with early stage cancer […]
In a 1909 manuscript titled “Ueber den jetzigen Stand der Chemotherapie” (“About the Current State of Chemotherapy”), Nobel laureate Paul Ehrlich proclaimed, “We must learn to aim in a chemical sense.” What did he mean? Ehrlich was referring to his “magic bullet” theory of chemical specificity, the observation that certain drugs can eliminate disease-causing entities […]